CLBS-119

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameCLBS-119
Drug Alias NameAutologous Peripheral Blood Derived CD34+ Cells (Caladrius Biosciences)CLBS-119CLBS119
ClassificationCell and gene therapy > Cell therapy
Mechanisms of ActionCell replacements
TargetsNot applicable
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesCaladrius Biosciences Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesLisata Therapeutics Inc
Active IndicationsN/A
Inactive IndicationsCoronavirus Disease 2019 (COVID-19)

Other Information

ATC CodeN/A
Related LinksN/A